29
Jun
2026
The Rise, Fall, and Rise (and Fall…?) of Cell and Gene Therapy
More than $14 billion in announced acquisition value has flowed into in vivo cell therapy companies over the last 18 months. Lilly acquired Kelonia, AbbVie bought Capstan, BMS acquired Orbital, and AstraZeneca bought EsoBiotec, to name a few. These acquisitions demonstrate that we’re getting closer to the day when single injections that reprogram cells can fight disease without complex shipping logistics,... Read More